Caredx Inc Revenue Growth Rates (CDNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Caredx Inc   (NASDAQ: CDNA)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CDNA's Revenue Growth by Quarter and Year

Caredx Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CDNA/growth
https://api.csimarket.com/api/v1/companies/CDNA/fundamentals
https://api.csimarket.com/api/v1/companies/CDNA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CDNA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 139.36
2nd Quarter June 131.95
1st Quarter March 117.70
FY 389.01

CDNAs Annual Revenue
Caredx Inc 's Revenue in the fiscal year 2025 $ 379.81 millions
Caredx Inc 's Revenue in the fiscal year 2024 $ 333.79 millions
Caredx Inc 's Revenue in the fiscal year 2023 $ 280.32 millions
Caredx Inc 's Revenue in the fiscal year 2022 $ 321.79 millions
Caredx Inc 's Revenue in the fiscal year 2021 $ 296.40 millions




CDNA Revenue third quarter 2026 Y/Y Growth Comment
Caredx Inc achieved in the third quarter 2026, above Company average Revenue growth of 39.28% year on year, to $ 139.36 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 2 other companies have achieved higher Revenue growth. While Caredx Inc ' s Revenue rise of 39.28% ranks overall at the positon no. 454 in the third quarter 2026.


CDNA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 39.28 %
2nd Quarter June 52.23 %
1st Quarter March 38.98 %
FY   -

Financial Statements
Caredx Inc 's third quarter 2026 Revenue $ 139.36 millions CDNA's Income Statement
Caredx Inc 's third quarter 2025 Revenue $ 100.06 millions Quarterly CDNA's Income Statement


CDNA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.62 %
2nd Quarter June 12.11 %
1st Quarter March 8.59 %
FY (Year on Year)   -


Back to CDNA Growth rate Comparisons >> Back to CDNA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #115
Overall #454

Revenue Y/Y Growth Statistics
High Average Low
88.03 % 30.83 % -20.41 %
(Jun 30 2019)   (Mar 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #115
Overall #454
Revenue Y/Y Growth Statistics
High Average Low
88.03 % 30.83 % -20.41 %
(Jun 30 2019)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Caredx Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
63.59 % 7 % -12.95 %
(Jun 30 2016)  


CDNA's III. Quarter Q/Q Revenue Comment
Caredx Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.62% quarter on quarter, to $ 139.36 millions.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Caredx Inc 's Revenue growth quarter on quarter, overall rank is 734.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #121
Overall #734
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #8
Healthcare Sector #121
Overall #734
Revenue Q/Q Growth Statistics
High Average Low
63.59 % 7 % -12.95 %
(Jun 30 2016)  


CDNA's III. Quarter Q/Q Revenue Comment
Caredx Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.62% quarter on quarter, to $ 139.36 millions.

Within Medical Laboratories industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Caredx Inc 's Revenue growth quarter on quarter, overall rank is 734.


Caredx Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 497.40
Y / Y Revenue Growth (TTM) 38.94 %
Year on Year Revenue Growth Overall Ranking # 1131
Seqeuential Revenue Change (TTM) 8.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 2780


Cumulative Revenue growth Comment
Caredx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 38.94% year on year, to $ 497 millions if the fiscal year would have ended in Sep 30 2026.
Caredx Inc 's trailing twelve months Revenue growth was higher than company's average 29.69% and higher than 34.41% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 8.58 % from $458.09 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at29.69%.

In the Healthcare sector 209 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 519 to 1131.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 210
Overall # 1131

Revenue TTM Y/Y Growth Statistics
High Average Low
80.54 %
 29.69 %
-13.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 391
S&P 500 # 2780
Cumulative Revenue growth Comment
Caredx Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 38.94% year on year, to $ 497 millions if the fiscal year would have ended in Sep 30 2026.
Caredx Inc 's trailing twelve months Revenue growth was higher than company's average 29.69% and higher than 34.41% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 8.58 % from $458.09 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at29.69%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 8.58 % increase from $458.09 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 209 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 519 to 1131.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 210
Overall # 1131

Revenue TTM Y/Y Growth Statistics
High Average Low
80.54 %
29.69 %
-13.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 391
S&P 500 # 2780




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CDNA's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions


About Caredx Inc Revenue Growth Rates (CDNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Caredx Inc (CIK 1217234).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001217234-26-000061
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Caredx Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.